免疫性血小板减少症的治疗进展

侯明

doi:10.13201/j.issn.1004-2806.2020.01.002

免疫性血小板减少症的治疗进展

侯明^,

- 山东大学齐鲁医院血液科(济南, 250012)

详细信息

通讯作者: 山东大学关键岗位教授、博士生导师,泰山学者特聘专家、山东省医学领军人才,卫生部有突出贡献中青年专家,享受国务院政府特殊津贴。兼任ITP国际工作组指南制定专家组成员、亚太血栓与止血学会执委、美国血液学会资深会员、中华医学会血液学分会常委、中华医学会血液学分会血栓与止血学组副组长、中国病理生理协会实验血液学会常委、中国医师学会血液科医师分会副会长。侯明教授先后主持承担了国家重点基础研究973项目2项、卫生部临床学科重点项目3项、国家自然科学基金5项、山东省自然科学基金3项、泰山学者基金项目、山东省医学领军人才培养工程。在原发免疫性血小板减少症发病机制、特异诊断及治疗方面取得一系列创新性成果,多次获得教育部自然科学奖、科学技术进步奖等重要奖励。侯明教授致力于原发免疫性血小板减少症的基础与临床研究,在国内外处于领先水平,其中15篇研究报道发表于国际顶尖血液学杂志Blood,先后带头主持起草4版原发免疫性血小板减少症诊治中国专家共识或指南,为国内乃至国际原发免疫性血小板减少症诊断治疗领域首屈一指的医学大家。,E-mail:houming@medmail.com.cn

中图分类号: R558.2

收稿日期: 2019-11-27

Progress in the treatment of immune thrombocytopenia

HOU Ming^,

More Information

Corresponding author: HOU Ming, E-mail: houming@medmail.com.cn

Received Date: 27 November 2019

摘要

摘要: 原发免疫性血小板减少症（immune thrombocytopenia,ITP）是一种复杂的多种机制共同参与的获得性自身免疫性疾病。虽然原发性ITP是一种良性疾病,但目前尚无法根治,也不能改变其自然病程,其死亡率与正常人群无明显差异,患者多死于感染而非出血。因此,ITP的治疗目的是使患者血小板计数（PLT）提高到安全水平,降低出血风险,改善患者的生活质量。原则上,对于原发性ITP,如果其PLT高于30×109/L,无出血,血小板功能及凝
- 免疫性血小板减少症 /
- 治疗
- immune thrombocytopenia /
- treatment

HTML全文

参考文献(28)

[1]	Mashhadi MA,Kaykhaei MA,Sepehri Z,et al.Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia[J].Daru,2012,20:7.
[2]	DasGupta RK,Levine L,Wiczer T,et al.Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia[J].J Oncol Pharm Pract,2019,25:567-576.
[3]	Samkari H,Kuter DJ.Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia[J].Am J Hematol,2018,93:1501-1508.
[4]	Al-Samkari H,Kuter DJ.Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia[J].Ther Adv Hematol,2019 Apr 11;10:2040620719841735.doi:10.1177/2040620719841735.eCollection 2019.
[5]	Ghanima W,Cooper N,Rodeghiero F,et al.Thrombopoietin receptor agonists:ten years later[J].Haematologica,2019,104:1112-1123.
[6]	Raslova H,Vainchenker W,Plo I.Eltrombopag,a potent stimulator of megakaryopoiesis[J].Haematologica,2016,101:1443-1445.
[7]	Di Buduo CA,Currao M,Pecci A,et al.Revealing eltrombopags promotion of human megakaryopoiesis through AKT/ERK dependent pathway activation[J].Haematologica,2016,101:1479-1488.
[8]	González-Porras JR,Godeau B,Carpenedo M.Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia[J].Ther Adv Hematol,2019 May 9;10:2040620719837906.doi:10.1177/2040620719837906.eCollection 2019.
[9]	Cantoni S,Carpenedo M,Mazzucconi MG,et al.Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients:a retrospective collaborative survey from Italian hematology centers[J].Am J Hematol,2018,93:58-64.
[10]	González-Porras JR,Mingot-Castellano ME,Andrade MM,et al.Use of eltrombopag after romiplostim in primary immune thrombocytopenia[J].Br J Haematol,2015,169:111-116.
[11]	Khellaf M,Viallard JF,Hamidou M,et al.A retrospective pilot evaluation of switching thrombopoietic receptor agonists in immune thrombocytopenia[J].Haematologica,2013,98:881-887.
[12]	Mahevas M,Fain O,Ebbo M,et al.The temporary use of thrombopoietin receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia.Results of a French observational study[J].Br J Haematol,2014,165:865-869.
[13]	Bao W,Bussel JB,Heck S,et al.Improved regulatory T cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents[J].Blood,2010,116:4639 -4645.
[14]	Kuter DJ,Newland A,Chong BH.Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year:a subgroup analysis of integrated data from completed romiplostim studies[J].Br J Haematol,2019,185:503-513.
[15]	Bussel JB,Kuter DJ,George JN,et al.AMG 531,a thrombopoiesis stimulating protein,or chronic ITP[J].N Engl J Med,2006,355:1672-1681.
[16]	Patel VL,Mahévas M,Lee SY,et al.Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia[J].Blood,2012,119:5989-5995.
[17]	Provan D,Butler T,Evangelista ML,et al.Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults[J].Haematologica,2007,92:1695-1698.
[18]	Auger S,Duny Y,Rossi JF,et al.Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura:a meta-analysis[J].Br J Haematol,2012,158:386-398.
[19]	Marangon M,Vianelli N,Palandri F,et al.Rituximab in immune thrombocytopenia:gender,age,and response as predictors of long-term response[J].Eur J Haematol,2017,98:371-377.
[20]	Kojouri K,Vesely SK,Terrell DR,et al.Splenectomy for adult patients with idiopathic thrombocytopenic purpura:a systematic review to assess long-term platelet count responses,prediction of response,and surgical complications[J].Blood,2004,104:2623-2634.
[21]	Stasi R,Stipa E,Masi M,et al.Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura[J].Am J Med,1995,98:436-442.
[22]	Gómez-Almaguer D.Eltrombopag-based combination treatment for immune thrombocytopenia[J].Ther Adv Hematol,2018,9:309-317.
[23]	Li Y,Wang YY,Fei HR,et al.Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP[J].Eur Rev Med Pharmacol Sci,2015,19:1583-1588.
[24]	Gómez-Almaguer D,Herrera Rojas MA,Jaime Pérez JC,et al.Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults[J].Blood,2014,123:3906-3908.
[25]	Magro D,Levato L,Eugenio P,et al.High dose dexamethasone and eltrombopag in chronic immune thrombocytopenia:a single institution experience[J].Haematologica,2017,102:117.
[26]	Li J,Wang Z,Dai L,et al.Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia[J].Clin Dev Immunol,2013,2013:548085.
[27]	Miano M,Rotulo GA,Palmisani E,et al.Sirolimus as a rescue therapy in children with immune thrombocytopenia refractory to mycophenolate mofetil[J].Am J Hematol,2018,93:E175-E177.
[28]	Connell NT,Berliner N.Fostamatinib for the treatment of chronic immune thrombocytopenia[J].Blood,2019,133:2027-2030.